文献速递新生儿儿童心血管与肾脏

早产儿布洛芬关闭动脉导管未闭的个体化治疗药物监测新策略

Novel strategy to personalise use of ibuprofen for closure of patent ductus arteriosus in preterm neonates.
PubMed 文献 · Arch Dis Child · 2021-05-11

这项前瞻性单中心开放标签药代动力学研究在≤28+6周早产儿中探索用治疗药物监测个体化布洛芬关闭PDA。结论是首日单次采血即可预测目标暴露,从而个体化给药。

要点

  • 首日给药后8小时起,布洛芬浓度与3天目标暴露AUC0-72h强相关。
  • 首剂后8小时布洛芬浓度>20.5 mg/L对应90%概率达到目标暴露。
  • 首日单次采血即可预测目标暴露,支持个体化布洛芬给药。

核心结论

  • 首日单次采血可预测早产儿布洛芬3天目标暴露AUC0-72h>900 mg·hour/L,从而支持个体化给药。

研究设计与样本

  • 前瞻性、单中心、开放标签药代动力学研究,纳入胎龄≤28+6周、口服布洛芬关闭PDA的早产儿。
  • 采用群体药代动力学建模与模拟获取参数、浓度-时间曲线和暴露指标。

主要发现

  • 首日给药后8小时起,布洛芬浓度与AUC0-72h呈强相关。
  • 首剂后8小时布洛芬浓度>20.5 mg/L与90%概率达到目标暴露AUC0-72h>900 mg·hour/L相关。

关键数值与推荐

  • 目标暴露定义为前3天AUC0-72h>900 mg·hour/L。
  • 首剂后8小时布洛芬浓度>20.5 mg/L对应90%概率达到目标暴露。

临床怎么用

  • 可考虑在布洛芬首日给药后8小时单次采血测浓度,用于预判是否达到3天目标暴露并个体化调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Exploration of a novel therapeutic drug monitoring (TDM) strategy to personalise use of ibuprofen for closure of patent ductus arteriosus (PDA) in preterm neonates. DESIGN: Prospective, single-centre, open-label, pharmacokinetics study in preterm neonates. SETTING: Neonatal intensive care unit at McMaster Children's Hospital. PATIENTS: Neonates with a gestational age ≤28+6 weeks treated with oral ibuprofen for closure of a PDA. METHODS: Population pharmacokinetic parameters, concentration-time profiles and exposure metrics were obtained using pharmacometric modelling and simulation. MAIN OUTCOME MEASURE: Association between ibuprofen plasma concentrations measured at various sampling time points on the first day of treatment and attainment of the target exposure over the first 3 days of treatment (AUC0-72h >900 mg·hour/L). RESULTS: Twenty-three preterm neonates (median birth weight 780 g and gestational age 25.9 weeks) were included, yielding 155 plasma ibuprofen plasma samples. Starting from 8 hours' postdose on the first day, a strong correlation between ibuprofen concentrations and AUC0-72h was observed. At 8 hours after the first dose, an ibuprofen concentration >20.5 mg/L was associated with a 90% probability of reaching the target exposure. CONCLUSION: We designed a novel and practical TDM strategy and have shown that the chance of reaching the target exposure (AUC0-72h >900 mg·hour/L) can be predicted with a single sample collection on the first day of treatment. This newly acquired knowledge can be leveraged to personalise ibuprofen dosing regimens and improve the efficacy of ibuprofen use for pharmacological closure of a PDA.

来源:Arch Dis Child,查看原文。版权归原作者所有。

引用

  1. Samiee-Zafarghandy S, van Donge T, Fusch G, et al. Novel strategy to personalise use of ibuprofen for closure of patent ductus arteriosus in preterm neonates. Arch Dis Child. 2021. PMID: 33975823. doi:10.1136/archdischild-2020-321381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。